Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study.

Determination of ASP3258, a novel phosphodiesterase type 4 inhibitor, in rat plasma by high-performance liquid chromatography with fluorescence detection and its application to pharmacokinetic study.
复制标题

DOI:
10.1002/bmc.3262
复制
发表时间:
2015-02
期刊:
Biomedical chromatography : BMC
影响因子:
--
通讯作者:
Yoshiaki Ohtsu;F. Takanuki;Yasuhisa Fukunaga;K. Noguchi
Yoshiaki Ohtsu;F. Takanuki;Yasuhisa Fukunaga;K. Noguchi
中科院分区:
其他
文献类型:
--
作者:
Yoshiaki Ohtsu;F. Takanuki;Yasuhisa Fukunaga;K. Noguchi

文献摘要

被引文献

相似文献

强效磷酸二酯酶4抑制剂ASP 3258含有一个羧酸部分和一个萘啶环,是一种新型哮喘和慢性阻塞性肺病治疗药物。为了支持ASP 3258的药物开发,我们开发并验证了一种测定大鼠血浆中ASP 3258的简单方法。加入类似物AS 1406604 -00作为内标物后,在酸性条件下使用C18键合固相萃取柱处理血浆样品,并进样至具有荧光检测的高效液相色谱系统中。采用Shiseido Capcell Pak C18 UG 120色谱柱(3.0 × 150 mm,5 µm),以乙腈-0.5%乙酸(50:50,v/v)为移动的相进行色谱分离。用荧光检测器监测HPLC洗脱液,激发波长设定为315 nm,发射波长设定为365 nm。校准曲线在2.5-250 ng/mL范围内呈线性。验证数据表明,该方法具有选择性、灵敏度和准确度。此外,本方法成功地应用于大鼠血浆样品的药代动力学研究。
The potent phosphodiesterase 4 inhibitor ASP3258 contains a carboxylic acid moiety and a naphthyridine ring and is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease. To support the drug development of ASP3258, we developed and validated a simple method for its determination in rat plasma. Following the addition of the analog AS1406604-00 as an internal standard, plasma samples were processed using C18 -bonded solid-phase extraction cartridges under acidic conditions and injected into a high-performance liquid chromatography system with fluorescence detection. Chromatographic separation was achieved on a Shiseido Capcell Pak C18 UG120 column (3.0 × 150 mm, 5 µm) with a mobile phase consisting of acetonitrile-0.5% acetic acid (50:50, v/v). HPLC eluent was monitored with a fluorescence detector set at a wavelength of 315 nm for excitation and 365 nm for emission. The calibration curve was linear over a range of 2.5-250 ng/mL. Validation data demonstrated that the method is selective, sensitive and accurate. In addition, the present method was successfully applied to rat plasma samples from a pharmacokinetic study.